Better PrEParation for HIV prevention in minority groups

IF 12.1 1区医学 Q1 UROLOGY & NEPHROLOGY

Nature Reviews Urology Pub Date : 2024-12-06 DOI:10.1038/s41585-024-00981-w

Louise Lloyd

引用次数: 0

Abstract

In a phase III, double-blind, randomized, active-controlled trial, receipt of twice-yearly subcutaneous lenacapavir every 26 weeks as pre-exposure prophylaxis (PrEP) significantly reduced HIV incidence in cisgender men, transgender women, transgender men and gender non-binary persons. Of 3,265 included participants, 2 in the lenacapavir group were diagnosed with HIV (0.10 per 100 person-years) compared with 9 people receiving daily oral emtricitabine–tenofovir disoproxil fumarate (0.93 per 100 person-years) and a background incidence of 2.37 per 100 person-years. No safety concerns were identified. Thus, this treatment regimen has promise for these at-risk populations.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Urology 医学-泌尿学与肾脏学

CiteScore

12.50

自引率

2.60%

发文量

123

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Urology is part of the Nature Reviews portfolio of journals.Nature Reviews' basic, translational and clinical content is written by internationally renowned basic and clinical academics and researchers. This journal targeted readers in the biological and medical sciences, from the postgraduate level upwards, aiming to be accessible to professionals in any biological or medical discipline. The journal features authoritative In-depth Reviews providing up-to-date information on topics within a field's history and development. Perspectives, News & Views articles, and the Research Highlights section offer topical discussions and opinions, filtering primary research from various medical journals. Covering a wide range of subjects, including andrology, urologic oncology, and imaging, Nature Reviews provides valuable insights for practitioners, researchers, and academics within urology and related fields.